Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
  • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
  • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4858—Organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
  • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4816—Wall or shell material
  • A61K9/4825—Proteins, e.g. gelatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

• the present invention relates to a pharmaceutical composition comprising specific 11-deoxy-prostaglandin compound, method for stabilizing said therapeutically effective 11-deoxy-prostaglandin compound and a soft gelatin capsule formulation comprising the 11-deoxy- prostaglandin compound as an active ingredient.
• Prostaglandin has a prostanoic acid structure indicated by the formula: ( ⁇ Cha i n ) ( ⁇ chain) and there are many prostaglandins expressing a variety of therapeutic effects.
• 11-deoxy-prostaglandin compounds such as 11- deoxy-15-keto-16, 16-difluoro prostaglandin Ei:
• a further object of the present invention is to provide a soft gelatin capsule.
• a pharmaceutical composition comprising a 11-deoxy- prostaglandin compound represented by the formula (I) :
• L and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy (lower) alkyl, lower alkanoyloxy or oxo, wherein the five-membered ring may optionally have at least one double bond;
• A is -CH 3 , -CH 2 OH, -COCH 2 OH, -COOH or a functional derivative thereof;
• Ri is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon, which is unsubstituted or substituted with halogen, lower alkyl, hydroxy, oxo, aryl or heterocyclic group, and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur;
• R 0 is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkyl, lower alkoxy, lower alkanoyloxy, cyclo (lower) alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, heterocyclic group or hetrocyclic-oxy group; lower alkoxy; lower alkanoyloxy; cyclo (lower) alkyl; cyclo (lower) alkyloxy; aryl; aryloxy; heterocyclic group; heterocyclic-oxy group, and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur, and a fatty acid ester.
• a method for stabilizing the 11-deoxy-prostaglandin compound defined as above which comprises mixing the 11- deoxy-prostaglandin compound and a fatty acid ester is provided.
• a soft gelatin capsule formulation which comprises a soft gelatin capsule shell comprising a polyol and/or sugar alcohol as a plasticizer, and a pharmaceutical composition comprising the above defined 11-deoxy-prostaglandin compound and a pharmaceutically acceptable vehicle, wherein the composition is incorporated in the gelatin capsule shell.
• a more preferred 11-deoxy-prostaglandin compound used in the present invention is represented by the formula (ID :
• Z is
• R 4 and R5 are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy (lower) alkyl, wherein R 4 and R 5 are not hydroxy and lower alkoxy at the same time;
• Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkyl, lower alkoxy, lower alkanoyloxy, cyclo (lower) alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, heterocyclic group or hetrocyclic-oxy group; lower alkoxy; lower alkanoyloxy; cyclo (lower) alkyl; cyclo (lower) alkyloxy; aryl; aryloxy; heterocyclic group; heterocyclic-oxy group, and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and L, N, A and Ri are the same as defined above.
• a group of particularly preferable 11-deoxy- prostaglandin compounds among the above-described compounds is represented by the formula (III) :
• Xi and X 2 are hydrogen, lower alkyl, or halogen
• R.2 is a single bond or lower alkylene
• R.3 is lower alkyl, lower alkoxy, lower alkanoyloxy, cyclo (lower) alkyl, cyclo (lower) alkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group, and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and
• Ri and Ra represent an aliphatic hydrocarbon that include one or more double bonds and/or triple bonds that are isolatedly, separately or serially present between carbon atoms of the main and/or side chains. According to the usual nomenclature, an unsaturated bond between two serial positions is represented by denoting the lower number of the two positions, and an unsaturated bond between two distal positions is represented by denoting both of the positions.
• lower or medium aliphatic hydrocarbon refers to a straight or branched chain hydrocarbon group having 1 to 14 carbon atoms (for a side chain, 1 to 3 carbon atoms are preferable) and preferably 1 to 10, especially 6 to 10 carbon atoms for Ri and 1 to 10, especially 1 to 8 carbon atoms for R a .
• halogen covers fluorine, chlorine, bromine and iodine.
• lower throughout the specification is intended to include a group having 1 to 6 carbon atoms unless otherwise specified.
• lower alkyl refers to a straight or branched chain saturated hydrocarbon group containing 1 to
• 6 carbon atoms and includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and hexyl .
• lower alkoxy refers to a group of lower alkyl-O-, wherein lower alkyl is defined as above.
• hydroxy (lower) alkyl refers to a lower alkyl as defined above which is substituted with at least one hydroxy group such as hydroxymethyl, 1-hydroxyethyl, 2- hydroxyethyl and 1-methyl-l-hydroxyethyl .
• lower alkanoyloxy refers to a group represented by the formula RCO-O-, wherein RCO- is an acyl group formed by oxidation of a lower alkyl group as defined above, such as acetyl.
• cyclo (lower) alkyl refers to a cyclic group formed by cyclization of a lower alkyl group as defined above but contains three or more carbon atoms, and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl .
• cyclo (lower) alkyloxy refers to the group of cyclo (lower) alkyl-O-, wherein cyclo (lower) alkyl is defined as above.
• aryl may include unsubstituted or substituted aromatic hydrocarbon rings (preferably monocyclic groups) , for example, phenyl, naphthyl, tolyl and xylyl.
• substituents are halogen atom and halogen substituted lower alkyl, wherein halogen atom and lower alkyl are as defined above.
• aryloxy refers to a group represented by the formula ArO-, wherein Ar is aryl as defined above.
• heterocyclic group may include mono- to tri-cyclic, preferably monocyclic heterocyclic group which is 5 to 14, preferably 5 to 10 membered ring having optionally substituted carbon atom and 1 to 4, preferably 1 to 3 of 1 or 2 type of hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom.
• heterocyclic group examples include furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, furazanyl, pyranyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, 2-pyrrolinyl, pyrrolidinyl, 2- imidazolinyl, imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, piperidino, piperazinyl, morpholino, indolyl, benzothienyl, quinolyl, isoquinolyl, purinyl, quinazolinyl, carbazolyl, acridinyl, phenanthridinyl, benzimidazolyl, benzimidazolinyl, benzothiazolyl, phenothia
• heterocyclic-oxy group means a group represented by the formula HcO-, wherein Hc is a heterocyclic group as described above.
• the term "functional derivative" of A includes salts (preferably pharmaceutically acceptable salts) , ethers, esters and amides.
• Suitable "pharmaceutically acceptable salts” include conventionally used non-toxic salts, for example a salt with an inorganic base such as an alkali metal salt (such as sodium salt and potassium salt) , an alkaline earth metal salt (such as calcium salt and magnesium salt) , an ammonium salt; or a salt with an organic base, for example, an amine salt (such as methylamine salt, dimethylamine salt, cyclohexylamine salt, benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, tris (hydroxymethylamino) ethane salt, monomethyl- monoethanolamine salt, procaine salt and caffeine salt) , a basic amino acid salt (such as arginine salt and lysine salt) , tetraalkyl ammonium salt and the like. These salts may be prepared by a conventional process, for example from the corresponding acid and base or by salt interchange.
• an alkali metal salt such
• ethers examples include alkyl ethers, for example, lower alkyl ethers such as methyl ether, ethyl ether, propyl ether, isopropyl ether, butyl ether, isobutyl ether, sec-butyl ether, t-butyl ether, pentyl ether and 1- cyclopropyl ethyl ether; and medium or higher alkyl ethers such as octyl ether, diethylhexyl ether, lauryl ether and cetyl ether; unsaturated ethers such as oleyl ether and linolenyl ether; lower alkenyl ethers such as vinyl ether, allyl ether; lower alkynyl ethers such as ethynyl ether and propynyl ether; hydroxy (lower) alkyl ethers such as hydroxyethyl ether and hydroxyisopropyl
• (lower) alkyl ethers such as methoxymethyl ether and 1- methoxyethyl ether; optionally substituted aryl ethers such as phenyl ether, tosyl ether, sec-butyl ether, t- butylphenyl ether, salicyl ether, 3, 4-di-methoxyphenyl ether and benzamidophenyl ether; and aryl (lower) alkyl ethers such as benzyl ether, trityl ether and benzhydryl ether.
• esters examples include aliphatic esters, for example, lower alkyl esters such as methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, sec-butyl ester, t-butyl ester, pentyl ester and 1- cyclopropylethyl ester; lower alkenyl esters such as vinyl ester and allyl ester; lower alkynyl esters such as ethynyl ester and propynyl ester; hydroxy (lower) alkyl ester such as hydroxyethyl ester; lower alkoxy (lower) alkyl esters such as methoxymethyl ester and 1-methoxyethyl ester; and optionally substituted aryl esters such as, for example, phenyl ester, tosyl ester, t-butylphenyl ester, salicyl ester, 3, 4-d
• the amide of A mean a group represented by the formula -CONR'R", wherein each of R' and R" is hydrogen atom, lower alkyl, aryl, alkyl- or aryl-sulfonyl, lower alkenyl and lower alkynyl, and include for example lower alkyl amides such as methylamide, ethylamide, dimethylamide and diethylamide; arylamides such as anilide and toluidide; and alkyl- or aryl-sulfonylamides such as methylsulfonylamide, ethylsulfonyl-amide and tolylsulfonylamide .
• L include hydroxy and oxo which provide a 5-membered ring structure of, so called, especially PGF or PGE type.
• A is -COOH, its pharmaceutically acceptable salt, ester and amide thereof.
• Preferred example of B is -CH 2 -CH 2 -, which provide the structure of so-called, 13, 14-dihydro type compound.
• Preferred example of Xi and X 2 is hydrogen, or that at least one of them is halogen, more preferably, both of them are halogen, especially, fluorine that provides a structure of, so called 16, 16-difluoro type compound.
• Preferred R 1 is a hydrocarbon containing 1-10 carbon atoms, preferably, 6-8 carbon atoms. Further, at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur.
• Ri examples include, for example, the following groups:
• -CH 2 -C C-CH 2 -CH 2 -CH 2 -, -CH 2 -CH 2 -CH 2 -CH 2 -CH (CH 3 ) -CH 2 -,
• Preferred Ra is a hydrocarbon containing 1-10 carbon atoms, more preferably 1-8 carbon atoms and especially 5-7 carbon atoms.
• the hydrocarbon of Ra may additionally have one or two side chains each having one carbon atom.
• Preferred R 2 is single bond.
• Preferred R 3 is lower alkyl and more preferably, alkyl having 4-6 carbon atoms.
• the lower alkyl of R 3 may additionally have one or two side chains each having one carbon atom.
• the typical examples of the present compounds are ll-deoxy-13, 14-dihydro-16, 16-difluoro-PGE or PGF compound, ll-deoxy-13, 14-dihydro-15-keto-16, 16-difluoro-PGE or PGF compound, 2-decarboxy-2- (2-carboxyethyl) -ll-deoxy-13, 14- dihydro-15-keto-16, 16-difluoro-PGE or PGF compound, or ll- deoxy-13, 14-dihydro-15-keto-16, 16-difluoro-20-ethyl-PGE or PGF compound and its derivative or analogue.
• the preferred examples of the compounds may include ll-deoxy-13, 14-dihydro-15-keto-16, 16-difluoro-PGEi, ll-deoxy-13, 14-dihydro-16, 16-difluoro-PGEi, ll-deoxy-13, 14- dihydro-15-keto-16, 16-difluoro-PGEi isopropyl ester, 2- decarboxy-2- (2-carboxyethyl) -ll-deoxy-13, 14-dihydro-15- keto-16, 16-difluoro-PGEi isopropyl ester, 2-decarboxy-2- (2- carboxyethyl) -ll-deoxy-13, 14-dihydro-15-keto-16, 16- difluoro-PGEi, ll-deoxy-13, 14-dihydro-15-keto-16, 16- difluoro-20-methyl-PGEi isopropyl ester, ll-deoxy-13, 14-
• the 11-deoxy- prostaglandin compound of formula (I) covers any isomers of formula (I) including the individual tautomeric isomers, the mixture thereof, or optical isomers, the mixture thereof, a racemic mixture, and other steric isomers.
• the pharmaceutical composition of the present invention comprises the above described 11-deoxy- prostaglandin compound and a fatty acid ester.
• fatty acid esters used in the present invention may include fatty acid esters obtained from a fatty acid and an alcohol, for example, saturated or unsaturated glycerides which may have a branched chain.
• Preferred fatty acid esters may include a medium or higher chain fatty acid having at least C6, preferably C6-24 carbon atoms, for example caproic acid (C6) , caprylic acid(C8), capric acid(ClO), lauric acid(C12), myristic acid (C14) , palmitic acid(C16), palmitoleic acid(C16), stearic acid(C18), oleic acid(C18), linoleic acid(C18), linolenic acid(C18), ricinolic acid(C18) and arachic acid(C20).
• Preferred alcohols which consists the fatty acid ester may comprise Cl-6 monovalent alcohol and polyols such as glycerine, polyethyleneglycol and propyleneg
• Preferred fatty acid esters may include a glyceride of a saturated or unsaturated fatty acid which may have a branched chain, a glycerine fatty acid ester and a propyleneglycol fatty acid ester. Two or more glycerides may be used as a mixture.
• Examples of the mixture of glycerides are mixture of caprylic acid triglyceride and capric acid triglyceride, vegetable oils such as castor oil, corn oil, olive oil, sesame oil, rape oil, salad oil, cottonseed oil, camellia oil, peanut oil, palm oil and sunflower oil.
• a fatty acid ester derived from a fatty acid and a monovalent alcohol is also preferably used.
• the fatty acid ester may preferably be an ester of a C8-20 fatty acid and a C2-3 monovalent alcohol, such as isopropyl miristate, isopropyl palmitate, ethyl linoleate and ethyl oleate.
• the composition of the present invention may be prepared by dissolving or dispersing the above described 11-deoxy-prostaglandin compound in the fatty acid ester.
• each of them may be dissolved in a solvent in which both of them are soluble respectively, and then the solutions may be combined.
• the amount of the fatty acid ester in the composition relative to the amount of the 11-deoxy- prostaglandin compound is not limited as long as the 11- deoxy-prostaglandin compound is stable in the composition.
• the amount of the fatty acid ester per one part of the 11-deoxy-prostaglandin compound may be 1-5,000,000, preferably, 5-1,000,000 and most preferably, 10-500,000 parts by weight.
• the pharmaceutical composition of the present invention may further comprise physiologically acceptable additives which do not provide adverse effect to the stability of the compound of formula (I) .
• the additives which may be employed in the present invention include, but not limited to, excipients, diluents, fillers, solvents, lubricants, adjuvants, binders, disintegrants, coatings, capuslating agents, ointment bases, suppository bases, aerozoles, emulsifiers, dispersing agents, suspensions, viscosity increasing agents, isotonic agents, buffers, analgesic agents, preservatives, anti-oxidants, corrigents, flavors, colorants, and functional agents such as cyclodextrin, biologically degradable polymers.
• the additives may be selected from those described in any of general textbooks in the pharmaceutical field.
• the composition of the present invention may further comprise one or more other pharmaceutically active ingredient.
• the dosage form of the composition is not specifically limited and is preferably in the form suitable for oral administration. More preferably, the composition of the present invention is in the form of capsule such as hard capsule or soft capsule.
• Sugar alcohol solution derived from corn starch and glycerine have been known that they can be used as plasticizer for manufacturing soft-gelatin capsules.
• Sugar alcohol solution derived from corn starch and glycerine have also been known to deteriorate the stability of 11- deoxy-prostaglandin compound recited in the instant application when admixed directly with the compound and therefore, the art would expect that sugar alcohols or polyols are not useful as plasticizer for manufacturing soft gelatin capsule to incorporate the 11-deoxy- prostaglandin compound of the invention as an active ingredient.
• soft gelatin capsule shell manufactured from gelatin and a sugar alcohol or a polyol as a plasticizer will not deteriorate the stability of 11-deoxy-prostaglandin compound of the invention when the composition comprising the 11-deoxy- prostaglandin compound and a fatty acid ester is incorporated in the soft gelatin capsule shell.
• the composition which is filled in the soft-gelatin capsule shell may be obtained by dissolving or dispersing the above-described 11-deoxy-prostaglandin compound in a pharmaceutically acceptable vehicle which is liquid at the room temperature.
• a pharmaceutically acceptable vehicle which is liquid at the room temperature.
• each of them may be dissolved in a solvent in which both of them are soluble respectively, and then the solutions may be combined.
• the pharmaceutically acceptable vehicle may be any of those employed for the manufacture of medicaments as long as they do not deteriorate the stability of the active ingredient, 11-deoxy-prostaglandin compound.
• composition to be filled in the soft gelatin capsule shell is a composition comprising the 11-deoxy-prostaglandin compound and a fatty acid ester.
• the amount of the vehicle in the composition relative to the amount of the 11-deoxy-prostaglandin compound is not limited as long as the 11-deoxy- prostaglandin compound is stable in the final formulation.
• the amount of the vehicle per one part of the 11-deoxy-prostaglandin compound may be 1-5,000,000, preferably, 5-1,000,000 and most preferably, 10-500,000 parts by weight.
• the pharmaceutical composition to be filled in the soft gelatin capsule may further comprise oil solvent other than the fatty acid ester such as mineral oil, liquid paraffin, and tocopherol .
• Polyols used in the present invention are alcohols having two or three hydroxy groups. Preferred examples of polyols may include glycerine, polyethyleneglycol and propyleneglycol .
• Sugar alcohol plasticizer used in the present invention is an alcohol obtained by hydrogen reduction of the aldehyde group of a saccharide.
• examples may comprise sorbitol, mannitol, maltitol, lactitol, palatinit, xylitol and erithyritol; and sugar alcohol solution derived from corn starch, i.e. a mixture of sorbitol, sorbitan, mannitol and hydrogenated starch hydrolysate, hydrogenated maltose starch syrup, i.e. a mixture of maltitol, sorbitol and oligosaccharide alcohol.
• Preferred sugar alcohols may include sorbitol, sorbitan, maltitol, sugar alcohol solution derived from corn starch and hydrogenated maltose starch syrup.
• sugar alcohol solution derived from corn starch and available on market under the name "Anidrisorb” or “Polysorb” is preferably used.
• the amount of the sugar alcohol used for preparing the shell of the soft gelatin capsule is not specifically limited as long as the physical properties of the resulting capsule is not deteriorated.
• the amount of sugar alcohol plasticizer is 20-60 parts by weight, preferably, 30-50 parts by weight per 100 parts by weight of gelatin.
• the soft gelatin capsule formulation comprising the 11-deoxy-prostaglandin compound as an active ingredient may be manufactured by filling a composition comprising the 11-deoxy-prostaglandin compound and a pharmaceutically acceptable vehicle in soft gelatin capsule shell manufactured from gelatin and a plasticizer, polyol and/or sugar alcohol.
• a composition comprising the 11-deoxy-prostaglandin compound and a pharmaceutically acceptable vehicle
• soft gelatin capsule shell manufactured from gelatin and a plasticizer, polyol and/or sugar alcohol.
• Manufacture of soft gelatin capsule shell as well as filling the composition into the shell may be conducted according to a conventional manner.
• Compound 1 ll-deoxy-13, 14-dihydro-15-keto-16, 16- difluoro PGEl
• Compound 1 was dissolved in a vehicle shown in table 1 below to give 250 ⁇ g/g solution. Then, the solution was put in a hard grass container and heated at 55°C. The precise amount of Compound 1 in the solution was determined by means of HPLC (day 0) . The container was kept at 55°C for 10 days and after that the precise amount of the compound 1 was determined by means of HPLC (day 10) .
• the determination of the amount of the compound was carried out as follows. About 0.2g of the sample was mixed with exactly 2mL of internal standard solution and then with a dissolving agent shown in Table 1 to give 5mL of sample solution. About 5mg of the reference standard compound 1 was weighted precisely and added with acetonitrile to give exactly 5OmL solution. Exactly ImI of the solution was obtained and added with exactly 4mL of the internal standard solution, and then added with the dissolving agent to give 1OmL of reference solution.
• the fluorescent labeling agent was added to the respective solution, stirred and stood at room temperature for more than 30 minutes. After that, 2% acetic acid in acetonitrile was added to the solution, stirred and reacted at room temperature for more 30minutes to give the sample and standard solutions. Then, the respective solution in an amount that theoretically gives 3.6ng of compound 1 was loaded on the column and analyzed under the condition as follows : HPLC analysis condition:
• Miglyol 812N constituting fatty acids: caproic acid (C6) NMT 2.0%, caprylic acid (C8) 50.0-80.0%, capric acid (ClO) 20.0-50.0%, lauric acid (C12 NMT) 3.0%, and myristic acid (C14) NMT 1.0% (NF/EP) .
• Example 1 According to the results of Example 1 and Comparative Example 1, the stability of compound I was significantly improved by admixing the same with a fatty acid ester such as glyceride. In contrast, the stability of the compound 1 was poor in polyol such as glycerine, sugar, sugar alcohol, polyethylene glycol, polysorbate 80, and fatty acid.
• a fatty acid ester such as glyceride.
• polyol such as glycerine, sugar, sugar alcohol, polyethylene glycol, polysorbate 80, and fatty acid.
• the soft gelatin capsules obtained in the formulation example were kept at 40°C for 6 months or at 55°C for one month. After that, 20 capsules were swelled with purified water and ethyl acetate (HPLC grade) 1OmL was added thereto. The capsule was then cut opened and the liquid contained therein was obtained. ImL of the internal standard solution per lOO ⁇ g of theoretical amount of compound 1 was added to the liquid, and ethyl acetate (HPLC grade) was added so that the theoretical concentration of compound 1 was lO ⁇ g/mL to give a sample solution.
• the fluorescent labeling agent was added to the sample and standard solutions, stirred and reacted at room temperature.
• the sugar alcohol solution/polyol which decreased the stability of compound 1 when directly admixed with the compound will not affect the stability when used as plasticizer .

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Heart & Thoracic Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Cardiology (AREA)
• Vascular Medicine (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (2)

Family

ID=39720491

Family Applications (1)

Country Status (14)

Cited By (1)

Families Citing this family (5)

Citations (2)

Family Cites Families (13)

• 2008
  • 2008-07-16 EP EP08778342.9A patent/EP2178516B1/en not_active Not-in-force
  • 2008-07-16 MX MX2010000693A patent/MX339727B/es active IP Right Grant
  • 2008-07-16 AU AU2008276840A patent/AU2008276840B2/en not_active Ceased
  • 2008-07-16 WO PCT/JP2008/063222 patent/WO2009011449A2/en not_active Ceased
  • 2008-07-16 NZ NZ583203A patent/NZ583203A/en not_active IP Right Cessation
  • 2008-07-16 BR BRPI0814115A patent/BRPI0814115B8/pt active IP Right Grant
  • 2008-07-16 CN CN2013102926965A patent/CN103393618A/zh active Pending
  • 2008-07-16 RU RU2010105847/15A patent/RU2506072C2/ru active
  • 2008-07-16 KR KR1020107003612A patent/KR101485212B1/ko not_active Expired - Fee Related
  • 2008-07-16 EP EP20110158821 patent/EP2327398A3/en not_active Withdrawn
  • 2008-07-16 NZ NZ59527008A patent/NZ595270A/xx not_active IP Right Cessation
  • 2008-07-16 US US12/174,230 patent/US8969324B2/en active Active
  • 2008-07-16 JP JP2010516705A patent/JP5390519B2/ja not_active Expired - Fee Related
  • 2008-07-16 CA CA2691995A patent/CA2691995C/en active Active
  • 2008-07-16 CN CN2008800250368A patent/CN101808623B/zh not_active Expired - Fee Related
  • 2008-07-17 TW TW103122235A patent/TWI552772B/zh not_active IP Right Cessation
  • 2008-07-17 TW TW97127090A patent/TWI446912B/zh not_active IP Right Cessation
• 2009
  • 2009-12-31 IL IL203064A patent/IL203064B/en active IP Right Grant
• 2013
  • 2013-07-26 RU RU2013135403A patent/RU2651471C2/ru active
  • 2013-10-09 JP JP2013211759A patent/JP2014001247A/ja active Pending
• 2015
  • 2015-01-06 US US14/590,067 patent/US9254326B2/en not_active Expired - Fee Related
• 2018
  • 2018-04-12 RU RU2018113296A patent/RU2018113296A/ru not_active Application Discontinuation

Patent Citations (2)

Also Published As

Similar Documents

Legal Events